<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03646721</url>
  </required_header>
  <id_info>
    <org_study_id>DA1241_DM_Ib</org_study_id>
    <nct_id>NCT03646721</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM</brief_title>
  <official_title>A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, placebo-controlled, multiple ascending dose study to evaluate the&#xD;
      safety, tolerability, PK and PD of DA-1241 in healthy male subjects and subjects with T2DM&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 29, 2018</start_date>
  <completion_date type="Actual">May 7, 2020</completion_date>
  <primary_completion_date type="Actual">May 7, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-lead ECGs</measure>
    <time_frame>Throughout study duration, i.e., about 10 weeks (Part1) and about 14-16 weeks (Part2), respectively</time_frame>
    <description>Change from baseline in QTcF (msec)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Throughout study duration, i.e., about 10 weeks (Part1) and about 14-16 weeks (Part2), respectively</time_frame>
    <description>Change from baseline in blood pressure (mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Throughout study duration, i.e., about 10 weeks (Part1) and about 14-16 weeks (Part2), respectively</time_frame>
    <description>Change from baseline in heart rate (bpm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body temperature</measure>
    <time_frame>Throughout study duration, i.e., about 10 weeks (Part1) and about 14-16 weeks (Part2), respectively</time_frame>
    <description>Change from baseline in oral body temperature (°C)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>Throughout study duration, i.e., about 10 weeks (Part1) and about 14-16 weeks (Part2), respectively</time_frame>
    <description>Change from baseline in respiratory rate (bpm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination</measure>
    <time_frame>Throughout study duration, i.e., about 10 weeks (Part1) and about 14-16 weeks (Part2), respectively</time_frame>
    <description>Incidence and severity of clinical findings on physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory testing</measure>
    <time_frame>Throughout study duration, i.e., about 10 weeks (Part1) and about 14-16 weeks (Part2), respectively</time_frame>
    <description>Incidence and severity of clinical laboratory abnormality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse event</measure>
    <time_frame>Throughout study duration, i.e., about 10 weeks (Part1) and about 14-16 weeks (Part2), respectively</time_frame>
    <description>Incidence and severity of adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of DA-1241 (Cmax)</measure>
    <time_frame>Through the treatment period; 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum plasma DA-1241 concentration (Tmax)</measure>
    <time_frame>Through the treatment period; 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC)</measure>
    <time_frame>Through the treatment period; 9 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal elimination half-life (t½)</measure>
    <time_frame>Through the treatment period; 9 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total systemic clearance after oral administration (CL/F)</measure>
    <time_frame>Through the treatment period; 9 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F)</measure>
    <time_frame>Through the treatment period; 9 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Last dosing day AUCtau / First dosing day AUCtau)</measure>
    <time_frame>Through the treatment period; 9 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of DA-1241 excreted unchanged in the urine in each collection interval(Ae)</measure>
    <time_frame>Through the treatment period; 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative amount of DA-1241 excreted unchanged in the urine (Cum Ae)</measure>
    <time_frame>Through the treatment period; 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage fraction of DA-1241 excreted unchanged in the urine in each collection interval(Fe)</measure>
    <time_frame>Through the treatment period; 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative percentage fraction of DA-1241 excreted unchanged in the urine (Cum Fe)</measure>
    <time_frame>Through the treatment period; 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLR)</measure>
    <time_frame>Through the treatment period; 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose (FPG)</measure>
    <time_frame>Through the treatment period; 62 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2h-Postprandial glucose</measure>
    <time_frame>Through the treatment period; 56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the measurements versus (vs) time curve(AUE)</measure>
    <time_frame>Through the treatment period; 56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental AUEs after meal (iAUE)</measure>
    <time_frame>Through the treatment period; 56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weighted mean glucose (WMG)</measure>
    <time_frame>Through the treatment period; 56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental WMG (iWMG)</measure>
    <time_frame>Through the treatment period; 56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Insulin</measure>
    <time_frame>Through the treatment period; 56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated albumin</measure>
    <time_frame>Through the treatment period; 56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Through the treatment period; 56 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of key metabolite(s) of DA-1241</measure>
    <time_frame>Through the treatment period; 41 days</time_frame>
    <description>Key metabolite(s) of DA-1241 will be assessed in blood and urine.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>[Part1] DA-1241 : 6 subjects in each cohort(Cohort 1-3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will participate in 1 of 3 cohorts consisting of 8 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 6:2 (DA-1241 to matching placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[Part1] Placebo : 2 subjects in each cohort(Cohort 1-3)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will participate in 1 of 3 cohorts consisting of 8 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 6:2 (DA-1241 to matching placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[Part2] DA-1241 : 15 subjects in each cohort(Cohort 4-6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[Part2] Placebo : 5 subjects in each cohort(Cohort 4-6)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[Part2] Sitagliptin : 5 subjects in each cohort(Cohort 4-6)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-1241</intervention_name>
    <description>[Part1] Administration once daily for 28 days; Dose strength for each cohort (Cohort 1, 2 and 3) is planned as 50mg, 100mg and 200mg, respectively.&#xD;
[Part2] Administration once daily for 56 days; Dose strength for each cohort (Cohort 4, 5 and 6) is planned as 25mg, 50mg and 100mg, respectively.&#xD;
(Dose escalation and dose level decisions for subsequent cohorts will be made via interim dose escalation review meetings.)</description>
    <arm_group_label>[Part1] DA-1241 : 6 subjects in each cohort(Cohort 1-3)</arm_group_label>
    <arm_group_label>[Part2] DA-1241 : 15 subjects in each cohort(Cohort 4-6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>[Part1] Administration once daily for 28 days. [Part2] Administration once daily for 56 days.</description>
    <arm_group_label>[Part1] Placebo : 2 subjects in each cohort(Cohort 1-3)</arm_group_label>
    <arm_group_label>[Part2] Placebo : 5 subjects in each cohort(Cohort 4-6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>[Part2] Administration of Sitagliptin 100mg once daily for 56 days.</description>
    <arm_group_label>[Part2] Sitagliptin : 5 subjects in each cohort(Cohort 4-6)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        &lt;Part 1&gt;&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male subjects&#xD;
&#xD;
          2. Age ≥ 18 to ≤ 70 years of age.&#xD;
&#xD;
          3. Body mass index (BMI) ≥ 18.5 to ≤ 29.9 kg/m2.&#xD;
&#xD;
          4. Non-diabetic, fasting plasma glucose (FPG) of &lt; 100 mg/dL (measured with YSI at site;&#xD;
             one repeat test is allowed)&#xD;
&#xD;
          5. HbA1c &lt; 5.7 %&#xD;
&#xD;
          6. Non-smoker smoker, defined as: Non-smoker for &gt;12 months (ie, subject has not smoked&#xD;
             or used any tobacco product for the 12 months prior to the start of the study)&#xD;
             confirmed by a negative nicotine/cotinine test.&#xD;
&#xD;
          7. Male subjects must be surgically sterile, or engaged with partners of non-childbearing&#xD;
             potential, or if engaged with partners of childbearing potential, the subject and his&#xD;
             partner must be willing to use contraceptive methods until 3 months after the last day&#xD;
             of IP administration. Males must not donate sperms during the study and until 3 months&#xD;
             after the last day of IP administration.&#xD;
&#xD;
          8. Upon review, agree to participate and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Resting blood pressure (BP) &gt; 140/90 mmHg or &lt; 90/60 mmHg. Subjects BP may be&#xD;
             re-checked.&#xD;
&#xD;
          2. Participation in an investigational drug/device study within 30 days or 5 half-lives&#xD;
             within the last dose of any study drug, whichever is longer.&#xD;
&#xD;
          3. History of any serious adverse reaction or hypersensitivity to any of the&#xD;
             investigational product components or medicinal products with similar chemical&#xD;
             structure.&#xD;
&#xD;
          4. Have significant history of or current cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine, hematological, or neurological disorders or&#xD;
             abnormalities, or other major systemic disease that, according to the investigator,&#xD;
             would unduly risk the subject's safety or may impact the conduct of the study.&#xD;
&#xD;
          5. History of or acute significant gastrointestinal disorder (eg, peptic ulcers, severe&#xD;
             GERD), gastric surgery, including surgical treatment for obesity (eg, bariatric&#xD;
             surgery, gastric banding), gastric bypass or antrectomy or small bowel resection &gt;20cm&#xD;
             or any disorder that would interfere with the swallowing, absorption, distribution,&#xD;
             metabolism and excretion of the investigational product. Surgery for appendicitis is&#xD;
             acceptable.&#xD;
&#xD;
          6. Subject shows evidence of significant active neuropsychiatric disease, including&#xD;
             taking prescription medication for such diseases (including anti-depressant&#xD;
             /anti-anxiety medication),&#xD;
&#xD;
          7. Presence of clinically significant physical, laboratory, or ECG findings at Screening&#xD;
             that, in the opinion of the Investigator, may interfere with any aspect of study&#xD;
             conduct or interpretation of results, or may present a safety issue to that particular&#xD;
             subject. (Laboratory results may be re-checked once on a separate day per Investigator&#xD;
             discretion)&#xD;
&#xD;
          8. Long QT syndrome or family history of long QT syndrome or corrected QT interval (QTcF)&#xD;
             &gt; 450 ms at screening.&#xD;
&#xD;
          9. Liver function test results of AST and/or ALT ≥ 1.5 upper limit of normal (ULN).&#xD;
&#xD;
         10. Subject had a history of vaso-vagal syncope within 5 years.&#xD;
&#xD;
         11. History of any major surgery within 6 months.&#xD;
&#xD;
         12. History of any active infection, other than mild viral illness within 30 days prior to&#xD;
             dosing.&#xD;
&#xD;
         13. Known history or positive test of hepatitis B surface antigen (HBsAg), hepatitis C&#xD;
             antibody (HCV Ab), or human immunodeficiency virus type 1 (HIV-1) or 2 (HIV-2)&#xD;
             antibody.&#xD;
&#xD;
         14. Subjects with a positive urine nicotine/cotinine dipstick test.&#xD;
&#xD;
         15. History of alcohol abuse as judged by the Investigator within approximately 1 year.&#xD;
             Average weekly alcohol intake &gt; 21 units/week or are unwilling to stop alcohol&#xD;
             consumption from 24 hours prior to each dosing until discharged from the clinical&#xD;
             research unit (CRU). Positive alcohol test at Screening. (One unit of alcohol equals&#xD;
             about 250 mL of beer or lager, 100 mL of wine, or 35 mL of spirits).&#xD;
&#xD;
         16. History of illicit drug abuse, within approximately 1 year or evidence of current use&#xD;
             as judged by the Investigator. Positive drug test, including marijuana, at Screening.&#xD;
&#xD;
         17. Donation or loss of &gt; 500 mL of blood within 56 days.&#xD;
&#xD;
         18. Chronic use of over-the-counter or prescription medication within 7 or 14 days prior&#xD;
             to dosing per Investigator's discretion (apart from vitamin/mineral supplements,&#xD;
             occasional paracetamol, or birth control methods).&#xD;
&#xD;
         19. Unable to comply with the safety monitoring requirements of this clinical study or is&#xD;
             considered by the investigator to be an unsuitable candidate for the study.&#xD;
&#xD;
        &lt;Part 2&gt;&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects with T2DM &gt; 6 months.&#xD;
&#xD;
          2. Age ≥ 18 to ≤ 70 years of age.&#xD;
&#xD;
          3. Body mass index (BMI) ≤ 35 kg/m2.&#xD;
&#xD;
          4. On stable therapy with metformin monotherapy or metformin in combination with other&#xD;
             oral antidiabetic drugs (OADs) ≥ 1 month. (OADs except metformin will be washed-out&#xD;
             prior to the first dosing)&#xD;
&#xD;
          5. HbA1c ≥ 6.5 to ≤ 10%&#xD;
&#xD;
          6. Female and male subjects must agree to use highly effective methods of birth control&#xD;
             until 120 days after the last day of IP administration, or must be surgically sterile&#xD;
             or postmenopausal. Males must not donate sperm during the study and until 120 days&#xD;
             after the last day of IP administration.&#xD;
&#xD;
          7. Upon review, agree to participate and sign informed consent.&#xD;
&#xD;
        Exclusion Criteria :&#xD;
&#xD;
          1. A subject who has acute proliferative retinopathy or maculopathy, severe&#xD;
             gastroparesis, and/or severe neuropathy, especially autonomic neuropathy, as judged by&#xD;
             the Investigator.&#xD;
&#xD;
          2. Recurrent major hypoglycemia or hypoglycemic unawareness or recent ketoacidosis, as&#xD;
             judged by the Investigator.&#xD;
&#xD;
          3. Persistent blood pressure (BP) systolic or diastolic &gt; 160/90 mmHg or &lt; 90/60 mmHg.&#xD;
             Subjects BP may be re-checked per site SOP. Treatment with stable doses of&#xD;
             antihypertensive medication for 2 months prior to screening are allowed.&#xD;
&#xD;
          4. Pregnant or lactating women.&#xD;
&#xD;
          5. Participation in an investigational drug/device study within 30 days or 5 half-lives&#xD;
             within the last dose of any study drug, whichever is longer.&#xD;
&#xD;
          6. History of any serious adverse reaction or hypersensitivity to any of the&#xD;
             investigational product components or medicinal products with similar chemical&#xD;
             structure.&#xD;
&#xD;
          7. Current use of any prescribed or non-prescribed drugs (other than current treatment&#xD;
             for diabetes mellitus or birth control methods) that are known to interfere with&#xD;
             glucose or insulin metabolism, including but not limited to oral corticosteroids,&#xD;
             GLP-1 receptor agonists, monoamine oxidase (MAO) inhibitors, growth hormone,&#xD;
             non-selective β-blockers and lipid lowering medication. Lipid lowering medications&#xD;
             will be washed-out prior to the first dosing if subjects take medication for primary&#xD;
             prevention.&#xD;
&#xD;
          8. History of administration or current use of thiazolidinediones (TZDs).&#xD;
&#xD;
          9. Chronic use of acetaminophen, as acetaminophen is not allowed during the CGMS periods&#xD;
             in the study.&#xD;
&#xD;
         10. Unable to tolerate tape adhesive in the area of sensor placement.&#xD;
&#xD;
         11. Subject has any unresolved adverse skin condition in the area of sensor placement (eg,&#xD;
             psoriasis, rash, Staphylococcus infection).&#xD;
&#xD;
         12. History of or acute significant gastrointestinal disorder (eg, peptic ulcers, severe&#xD;
             GERD), gastric surgery, gastric bypass or antrectomy or small bowel resection or any&#xD;
             disorder that would interfere with the swallowing, absorption, distribution,&#xD;
             metabolism and excretion of the investigational product. Surgery for appendicitis is&#xD;
             acceptable.&#xD;
&#xD;
         13. History of renal disease or abnormal kidney function tests at Screening (eGFR &lt; 60&#xD;
             mL/min/1.73m2 as estimated using the MDRD equation).&#xD;
&#xD;
         14. Clinically significant abnormal laboratory test, in particular, elevated liver enzymes&#xD;
             (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels &gt; 2 times&#xD;
             the upper limit of normal (ULN)). (Laboratory results may be re-checked once on a&#xD;
             separate day per Investigator discretion)&#xD;
&#xD;
         15. Any history of heart disease, defined as symptomatic heart failure (New York Heart&#xD;
             Association class III or IV), myocardial infarction, coronary artery bypass graft&#xD;
             surgery, or angioplasty, unstable angina requiring medication, transient ischemic&#xD;
             attack, cerebral infarct, or cerebral hemorrhage.&#xD;
&#xD;
         16. History of any clinically or active significant gastrointestinal, cardiovascular,&#xD;
             hematological, psychiatric, renal, hepatic, pancreatic or neurological abnormality&#xD;
             that could interfere with the safety or results of this study as judged by the&#xD;
             Investigator.&#xD;
&#xD;
         17. Subject shows evidence of significant active neuropsychiatric disease. Subjects that&#xD;
             are stable and controlled by stable doses of selective serotonin reuptake inhibitors&#xD;
             (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), antipsychotics and&#xD;
             lithium for ≥ 6 months prior to screening are allowed.&#xD;
&#xD;
         18. Presence of clinically significant physical or ECG findings (eg, QTcF &gt; 450 msec for&#xD;
             males, QTcF &gt; 470 msec for females, left bundle branch block (LBBB)) at Screening&#xD;
             that, in the opinion of the Investigator, may interfere with any aspect of study&#xD;
             conduct or interpretation of results, or may present a safety issue to that particular&#xD;
             subject.&#xD;
&#xD;
         19. History of any major surgery within 6 months.&#xD;
&#xD;
         20. History of any active infection, other than mild viral illness within 30 days prior to&#xD;
             the first dosing.&#xD;
&#xD;
         21. Known history or positive test of hepatitis B surface antigen (HBsAg), hepatitis C&#xD;
             antibody (HCV Ab), or human immunodeficiency virus type 1 (HIV-1) or 2 (HIV-2)&#xD;
             antibody.&#xD;
&#xD;
         22. Smoking &gt; 10 cigarettes per day or equivalent use of any tobacco product (eg, nicotine&#xD;
             patch) within 6 months prior to Screening. Subjects must be able to refrain from&#xD;
             smoking during each in-house period.&#xD;
&#xD;
         23. History of alcohol abuse as judged by the Investigator within approximately 1 year.&#xD;
             Average weekly alcohol intake &gt; 21 units/week (males) and &gt; 14 units/week (females) or&#xD;
             are unwilling to stop alcohol consumption from 24 hours prior to each check-in for&#xD;
             in-house and outpatient visits and throughout the in-house periods until discharged&#xD;
             from the clinical research unit (CRU) and are unwilling to limit alcohol consumption&#xD;
             during outpatient periods. Positive alcohol test at Screening. (One unit of alcohol&#xD;
             equals about 250 mL of beer or lager, 100 mL of wine, or 35 mL of spirits).&#xD;
&#xD;
         24. History of illicit drug abuse, within approximately 1 year or evidence of current use&#xD;
             as judged by the Investigator. Positive drug test, including marijuana, at Screening.&#xD;
&#xD;
         25. Donation or loss of &gt; 500 mL of blood within 56 days.&#xD;
&#xD;
         26. Unable to comply with the safety monitoring requirements of this clinical study or is&#xD;
             considered by the investigator to be an unsuitable candidate for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>High Point Clinical Trials Center</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 21, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

